EyePoint Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022
For the full-year 2022, the company net product revenue estimated to exceed $39.5 million versus $35.3 million in 2021.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.985 USD | -5.27% | +17.15% | -55.95% |
26/06 | EyePoint Pharmaceuticals, Inc. Highlights Duravuyu Clinical and Regulatory Progress and Pipeline Innovation At R&D Day 2024 | CI |
26/06 | Transcript : EyePoint Pharmaceuticals, Inc. - Special Call |
1st Jan change | Capi. | |
---|---|---|
-55.95% | 55Cr | |
+56.77% | 85TCr | |
+32.85% | 63TCr | |
-1.12% | 36TCr | |
+14.47% | 32TCr | |
+12.39% | 30TCr | |
+14.38% | 24TCr | |
+16.50% | 23TCr | |
+15.74% | 18TCr | |
+3.18% | 17TCr |